Core Viewpoint - Hemostemix Inc. has been granted the trademark "KNOW YOUR HEALTH" in Japan, enhancing its intellectual property and global branding strategy in regenerative medicine and personalized health innovation [2][3]. Trademark Grant Details - The trademark registration covers Classes 1, 5, and 42, which include chemicals for scientific research, pharmaceutical preparations, and technological services in regenerative medicine [6]. - The registration number is International Registration No. 1744775, issued by the Japanese Patent Office [6]. Strategic Significance - The trademark aligns with Hemostemix's clinical programs, particularly the ACP-01 treatment for various ischemic and cardiopulmonary diseases, reinforcing the synergy between brand identity and product pipeline [5]. - The registration strengthens Hemostemix's global intellectual property portfolio, particularly in Japan, a leading market for medical research [10]. - The trademark allows for expanded therapeutic coverage, reflecting Hemostemix's leadership in developing autologous cell-based treatments for vascular and degenerative disorders [10]. - It provides a platform for global collaboration, enabling licensing and commercialization of innovations within Japan's regulatory framework for regenerative medicine [10]. CEO Commentary - The CEO expressed honor at the trademark grant, highlighting its importance for the company's commitment to improving patient health through autologous stem-cell therapy and enhancing partnerships with institutions in Asia [7]. Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, known for its VesCell™ (ACP-01) treatment, which has shown significant clinical results in various studies [8]. - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 for treating multiple ischemic conditions [8].

Core Viewpoint - Adia Med is leading an initiative to standardize umbilical cord stem cell use in the U.S., focusing on quality, safety, and accountability to enhance trust in regenerative medicine [1][2][3] Group 1: Initiative Overview - The initiative aims to establish rigorous best practices, including third-party verification and homologous applications, to redefine standards in regenerative medicine [1][3] - Adia Med plans to present these standards to the new head of the Department of Health and Human Services and the FDA to address inconsistencies in stem cell therapies [1][5] Group 2: Current Challenges - Patients have faced issues with low-quality or non-viable stem cells, leading to a lack of trust and limited potential in regenerative medicine [2][5] - Reports of patients receiving substandard stem cells are increasing, highlighting the urgent need for standardized practices [5][9] Group 3: Proposed Standards - Key pillars of the standardization framework include homologous use standards and strict quality control protocols for harvesting, processing, and storing stem cells [3][4] - Third-party verification will be required for all labs providing stem cell products, ensuring minimum stem cell count and viability for each batch [8] Group 4: Industry Impact - The initiative aims to enhance patient safety by reducing risks associated with poor-quality cells and ensuring treatment consistency across providers [9] - By establishing ethical standards, the initiative seeks to eliminate bad actors in the industry and restore trust among patients [9]